

* Risk factors or causes of frailty among CKD patients.

	Effect (descriptions)	Risk Difference	Frailty Assessment	Sample Size	CKD Severity	Reference
Biological						
Cardiovascular	Hypertension*	RR 1.6 (1.26-2.04)	Fried Phenotypes	205	CKD stage 5D (hemodialysis)	1*
	Peripheral vascular disease*	RR 1.58 (1.34-1.8)	Fried Phenotypes	205	CKD stage 5D (hemodialysis)	1*
	Left ventricular dysfunction*	RR 1.18 (1.03-1.36)	Fried Phenotypes	205	CKD stage 5D (hemodialysis)	1*
	Endothelial dysfunction	r= -0.367 (p= 0.004)	Fried Phenotypes	61	CKD stages 3-5	2
		OR 3.86 (1.00-14.88)				
Cerebrovascular	Cerebrovascular Accident	RR 1.34 (1.19-1.5)	Fried Phenotypes	205	CKD stage 5D (hemodialysis)	1*
Pulmonary	COPD	OR 1.68 (1.16-2.45)	Fried Phenotypes	10256	CKD stages 1-5	3
Immunological	Inflammatory					
	IL-6*	Worse frailty	Fried Phenotypes	762	CKD stage 5D (hemodialysis)	4*
	CRP	After	Fried	5888	Chronic kidney	5

			Fibrinogen	adjustment, OR 1.76 (1.28-2.41) to 1.50 (1.07- 2.09)	Phenotypes		insufficiency, serum creatinine ≥1.3mg/dL	
	Endocrinologic/ Metabolic	Diabetes	Frailty scores +0.7 points per year	Fried Phenotypes	762	CKD stage 5D (hemodialysis)	4*	
			OR 1.68 (1.16- 2.45)	Fried Phenotypes	10256	CKD stages 1-5	3	
		Obesity (IMC ≥ 30 kg/m²)	OR 6.63 (1.16- 36.77)	Fried Phenotypes	61	CKD stages 3-5	2	
		Higher parathyroid hormones (PTH)	r= 0.30 (p= 0.01)	Fried Phenotypes	61	CKD stages 3-5	2	
	Body Composition	Higher fat mass	r= 0.25 (p= 0.04)	Fried Phenotypes	61	CKD stages 3-5	2	
	Cancer	Cancer	OR 1.89 (1.19- 2.99)	Fried Phenotypes	10256	CKD stages 1-5	3	
	Arthritis	Arthritis	OR 3.34 (2.08- 5.38)	Fried Phenotypes	10256	CKD stages 1-5	3	
	Laboratory Data	eGFR (mL/min/1.72m^2)						

		eGFRcys <30	Frailty prevalence 2.8	Fried Phenotypes	336	CKD stages 1-4	6*
		eGFRcys 30-44	Frailty prevalence 2.1				
		eGFRcys >60	Referent				
		Serum Albumin Concentrations (g/dL)	Frailty scores -1.1 points per g/dL	Fried Phenotypes	762	CKD stage 5D (hemodialysis)	4*
		Serum Creatinine <4 mg/dL*	RR 1.46 (1.22-1.71)	Fried Phenotypes	205	CKD stage 5D (hemodialysis)	1*
		Testosterone, per 50% lower free testosterone*		Fried Phenotypes	440	CKD stage 5D (hemodialysis), men	7*
		being frail	OR 1.40 (1.05-1.53)				
		becoming frail over 12 months	OR 1.40 (1.07-1.73)				
		Hemoglobin	Adjusted, OR 1.76 (1.28-2.41) to 1.50 (1.07-2.09)	Fried Phenotypes	5888	Chronic kidney insufficiency, serum creatinine ≥1.3mg/dL	5
		LDL, HDL					
Lifestyle		Smoking*	RR 1.18 (1.04-	Fried	205	CKD stage 5D	1*

		1.34)	Phenotypes		(hemodialysis)	
Ethnicity	Hispanic*	Frailty scores +0.6 points per year	Fried Phenotypes	762	CKD stage 5D (hemodialysis)	⁴ *

Bibliography

1. YadlaM, JohnJ, MummadiM. A study of clinical assessment of frailty in patients on maintenance hemodialysis supported by cashless government scheme. *Saudi J Kidney Dis Transplant*. 2017. doi:10.4103/1319-2442.198102
2. MansurHN. Fragilidade na doença renal crônica: prevalência e fatores associados. 2012.
3. Wilhelm-LeenER, HallYN, MKT, ChertowGM. Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. *Am J Med*. 2009;122(7):664-71 e2. doi:10.1016/j.amjmed.2009.01.026
4. JohansenKL, DalrympleLS, DelgadoC, et al. Factors Associated with Frailty and Its Trajectory among Patients on Hemodialysis. *Clin J Am Soc Nephrol*. 2017;12(7):1100-1108. doi:10.2215/CJN.12131116
5. ShlipakMG, Stehman-BreenC, FriedLF, et al. The Presence of Frailty in Elderly Persons with Chronic Renal Insufficiency. *Am J Kidney Dis*. 2004;43(5):861-867. doi:10.1053/j.ajkd.2003.12.049
6. RoshanravanB, KhatriM, Robinson-CohenC, et al. A prospective study of frailty in nephrology-referred patients with CKD. *Am J Kidney Dis*. 2012;60(6):912-921. doi:10.1053/j.ajkd.2012.05.017
7. ChiangJM, KaysenGA, SegalM, ChertowGM, DelgadoC, JohansenKL. Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis. *Nephrol Dial Transplant*. 2018. doi:10.1093/ndt/gfy252